
GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China’s research labs are snapping up market share in the global pharmaceutical and biomedical …